Gilead Sciences (GILD) Interest Coverage Ratio (2009 - 2026)
Gilead Sciences' (GILD) quarterly Interest Coverage Ratio came in at 42.08 in Q2 2026, down 532.04% on a YoY basis from 9.74 in Q2 2025, and down 490.54% quarter-over-quarter from 10.78 in Q1 2026.
Powered by 
Analysis
Gilead Sciences (GILD) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Interest Coverage Ratio for 18 consecutive years, with 42.08 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest Coverage Ratio fell 532.04% year-over-year to 42.08; the trailing twelve-month figure through Jun 2026 stood at 2.5 (down 131.11% YoY), and the FY2025 full-year result was 9.79, up 475.33% from the prior year.
- Interest Coverage Ratio fell to 42.08 in Q2 2026 per GILD's latest filing, from 10.78 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 13.0 in Q3 2025 and bottomed at 42.08 in Q2 2026.
- Historically, Interest Coverage Ratio has averaged 4.42 across 5 years, with a median of 8.49 in 2025.
- The sharpest annual moves came in 2023 and 2026: Interest Coverage Ratio soared 795.59% in 2023, then plunged 532.04% in 2026.
- Over 5 years, Interest Coverage Ratio stood at 10.03 in 2022, then sank by 36.23% to 6.4 in 2023, then soared by 53.94% to 9.85 in 2024, then retreated by 20.99% to 7.78 in 2025, then sank by 640.86% to 42.08 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 42.08, 10.78, and 7.78 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.54 Bn | 192.56 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.55 Bn | 176.37 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 131.10 Bn | 123.25 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.62 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.69 Bn | 55.51 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 53.54 Bn | 48.40 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.10 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.80 Bn | 30.52 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.08 Bn | 29.08 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.08 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.08 |
| Mar 31, 2026 | 10.78 |
| Dec 31, 2025 | 7.78 |
| Sep 30, 2025 | 13.00 |
| Jun 30, 2025 | 9.74 |
| Mar 31, 2025 | 8.60 |
| Dec 31, 2024 | 9.85 |
| Sep 30, 2024 | 3.73 |
| Jun 30, 2024 | 11.16 |
| Mar 31, 2024 | -17.02 |
| Dec 31, 2023 | 6.40 |
| Sep 30, 2023 | 11.31 |
| Jun 30, 2023 | 7.24 |
| Mar 31, 2023 | 7.41 |
| Dec 31, 2022 | 10.03 |
| Sep 30, 2022 | 12.39 |
| Jun 30, 2022 | 8.38 |
| Mar 31, 2022 | 0.83 |
| Dec 31, 2021 | 3.95 |
| Sep 30, 2021 | 15.37 |